Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Hedge Funds

13G Filing: Balyasny Asset Management and Sunesis Pharmaceuticals Inc (SNSS)

Published on July 5, 2017 at 2:51 pm by Insider Monkey Staff in Hedge Funds

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Atlas Master Fund, Ltd 224,506 224,506 224,506 1.05%
Atlas Global 224,506 224,506 224,506 1.05%
Atlas Global Investments, Ltd 224,506 224,506 224,506 1.05%
Atlas Institutional Fund 224,506 224,506 224,506 1.05%
Atlas Institutional Fund, Ltd 224,506 224,506 224,506 1.05%
Atlas Global Japan Unit Trust 224,506 224,506 224,506 1.05%
Atlas Enhanced Master Fund, Ltd 1,310,494 1,310,494 1,310,494 6.11%
Atlas Enhanced Fund 1,310,494 1,310,494 1,310,494 6.11%
Atlas Enhanced Fund, Ltd 1,310,494 1,310,494 1,310,494 6.11%
Atlas Fundamental Trading Master Fund, Ltd 465,000 465,000 465,000 2.17%
Atlas Fundamental Trading Fund 465,000 465,000 465,000 2.17%
Atlas Fundamental Trading Fund, Ltd 465,000 465,000 465,000 2.17%
Balyasny Asset Management 2,000,000 2,000,000 2,000,000 9.32%
Dmitry Balyasny 2,000,000 2,000,000 2,000,000 9.32%

Follow Dmitry Balyasny's Balyasny Asset Management

Page 1 of 30 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

SUNESIS
PHARMACEUTICALS, INC.

(Name of Issuer)

COMMON STOCK

(Title of
Class of Securities)

867328700

(CUSIP Number)

June 23,
2017

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒
Rule 13d-1(c)

☐ Rule 13d-1(d)

The
information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 2 of 30 – SEC Filing

CUSIP No. 867328700 Page
2
of 30 Pages
  1 

NAMES OF
REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Atlas Master Fund, Ltd.
  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP*

(a)  ☐        (b)  ☐
  3

SEC USE ONLY
  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

Cayman

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 5   

SOLE VOTING POWER

224,506 (See Item 4)
6

SHARED VOTING POWER

None (See Item 4)
7

SOLE DISPOSITIVE POWER

224,506 (See Item 4)
8

SHARED DISPOSITIVE POWER

None
  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

224,506 (See Item 4)
10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES*  ☐

Not Applicable
11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (9)

1.05%
12

TYPE OF REPORTING PERSON*

CO

* SEE INSTRUCTIONS BEFORE FILLING OUT.

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 3 of 30 – SEC Filing

CUSIP No. 867328700 Page
3
of 30 Pages
  1 

NAMES OF
REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Atlas Global, LLC
  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP*

(a)  ☐        (b)  ☐
  3

SEC USE ONLY
  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 5   

SOLE VOTING POWER

224,506
6

SHARED VOTING POWER

None (See Item 4)
7

SOLE DISPOSITIVE POWER

224,506
8

SHARED DISPOSITIVE POWER

None (See Item 4)
  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

224,506 (See Item 4)
10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES*  ☐

Not Applicable
11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (9)

1.05%
12

TYPE OF REPORTING PERSON*

OO

* SEE INSTRUCTIONS BEFORE FILLING OUT.

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 4 of 30 – SEC Filing

CUSIP No. 867328700 Page
4
of 30 Pages
  1 

NAMES OF
REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Atlas Global Investments, Ltd.
  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP*

(a)  ☐        (b)  ☐
  3

SEC USE ONLY
  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

Cayman

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 5   

SOLE VOTING POWER

224,506
6

SHARED VOTING POWER

None (See Item 4)
7

SOLE DISPOSITIVE POWER

224,506
8

SHARED DISPOSITIVE POWER

None (See Item 4)
  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

224,506 (See Item 4)
10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES*  ☐

Not Applicable
11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (9)

1.05%
12

TYPE OF REPORTING PERSON*

CO

* SEE INSTRUCTIONS BEFORE FILLING OUT.

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 5 of 30 – SEC Filing

CUSIP No. 867328700 Page
5
of 30 Pages
  1 

NAMES OF
REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Atlas Institutional Fund, LLC
  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP*

(a)  ☐        (b)  ☐
  3

SEC USE ONLY
  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 5   

SOLE VOTING POWER

224,506
6

SHARED VOTING POWER

None (See Item 4)
7

SOLE DISPOSITIVE POWER

224,506
8

SHARED DISPOSITIVE POWER

None (See Item 4)
  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

224,506 (See Item 4)
10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES*  ☐

Not Applicable
11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (9)

1.05%
12

TYPE OF REPORTING PERSON*

OO

* SEE INSTRUCTIONS BEFORE FILLING OUT.

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 6 of 30 – SEC Filing

CUSIP No. 867328700 Page
6
of 30 Pages
  1 

NAMES OF
REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Atlas Institutional Fund, Ltd.
  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP*

(a)  ☐        (b)  ☐
  3

SEC USE ONLY
  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

Cayman

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 5   

SOLE VOTING POWER

224,506
6

SHARED VOTING POWER

None (See Item 4)
7

SOLE DISPOSITIVE POWER

224,506
8

SHARED DISPOSITIVE POWER

None (See Item 4)
  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

224,506 (See Item 4)
10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES*  ☐

Not Applicable
11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (9)

1.05%
12

TYPE OF REPORTING PERSON*

CO

* SEE INSTRUCTIONS BEFORE FILLING OUT.

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 7 of 30 – SEC Filing

CUSIP No. 867328700 Page
7
of 30 Pages
  1 

NAMES OF
REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Atlas Global Japan Unit Trust
  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP*

(a)  ☐        (b)  ☐
  3

SEC USE ONLY
  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

Cayman

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 5   

SOLE VOTING POWER

224,506
6

SHARED VOTING POWER

None (See Item 4)
7

SOLE DISPOSITIVE POWER

224,506
8

SHARED DISPOSITIVE POWER

None (See Item 4)
  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

224,506 (See Item 4)
10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES*  ☐

Not Applicable
11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (9)

1.05%
12

TYPE OF REPORTING PERSON*

OO

* SEE INSTRUCTIONS BEFORE FILLING OUT.

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 8 of 30 – SEC Filing

CUSIP No. 867328700 Page
8
of 30 Pages
  1 

NAMES OF
REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Atlas Enhanced Master Fund, Ltd.
  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP*

(a)  ☐        (b)  ☐
  3

SEC USE ONLY
  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

Cayman

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 5   

SOLE VOTING POWER

1,310,494
6

SHARED VOTING POWER

None (See Item 4)
7

SOLE DISPOSITIVE POWER

1,310,494
8

SHARED DISPOSITIVE POWER

None (See Item 4)
  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,310,494 (See Item 4)
10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES*  ☐

Not Applicable
11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (9)

6.11%
12

TYPE OF REPORTING PERSON*

CO

* SEE INSTRUCTIONS BEFORE FILLING OUT.

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 9 of 30 – SEC Filing

CUSIP No. 867328700 Page
9
of 30 Pages
  1 

NAMES OF
REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Atlas Enhanced Fund, L.P.
  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP*

(a)  ☐        (b)  ☐
  3

SEC USE ONLY
  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 5   

SOLE VOTING POWER

1,310,494
6

SHARED VOTING POWER

None (See Item 4)
7

SOLE DISPOSITIVE POWER

1,310,494
8

SHARED DISPOSITIVE POWER

None (See Item 4)
  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,310,494 (See Item 4)
10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES*  ☐

Not Applicable
11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (9)

6.11%
12

TYPE OF REPORTING PERSON*

OO

* SEE INSTRUCTIONS BEFORE FILLING OUT.

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 10 of 30 – SEC Filing

CUSIP No. 867328700 Page
10
of 30 Pages
  1 

NAMES OF
REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Atlas Enhanced Fund, Ltd.
  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP*

(a)  ☐        (b)  ☐
  3

SEC USE ONLY
  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

Cayman

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 5   

SOLE VOTING POWER

1,310,494
6

SHARED VOTING POWER

None (See Item 4)
7

SOLE DISPOSITIVE POWER

1,310,494
8

SHARED DISPOSITIVE POWER

None (See Item 4)
  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,310,494 (See Item 4)
10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES*  ☐

Not Applicable
11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (9)

6.11%
12

TYPE OF REPORTING PERSON*

CO

* SEE INSTRUCTIONS BEFORE FILLING OUT.

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 11 of 30 – SEC Filing

CUSIP No. 867328700 Page
11
of 30 Pages
  1 

NAMES OF
REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Atlas Fundamental Trading Master Fund, Ltd.
  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP*

(a)  ☐        (b)  ☐
  3

SEC USE ONLY
  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

Cayman

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 5   

SOLE VOTING POWER

465,000
6

SHARED VOTING POWER

None (See Item 4)
7

SOLE DISPOSITIVE POWER

465,000
8

SHARED DISPOSITIVE POWER

None (See Item 4)
  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

465,000 (See Item 4)
10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES*  ☐

Not Applicable
11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (9)

2.17%
12

TYPE OF REPORTING PERSON*

CO

* SEE INSTRUCTIONS BEFORE FILLING OUT.

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 12 of 30 – SEC Filing

CUSIP No. 867328700 Page
12
of 30 Pages
  1 

NAMES OF
REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Atlas Fundamental Trading Fund, L.P.
  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP*

(a)  ☐        (b)  ☐
  3

SEC USE ONLY
  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 5   

SOLE VOTING POWER

465,000
6

SHARED VOTING POWER

None (See Item 4)
7

SOLE DISPOSITIVE POWER

465,000
8

SHARED DISPOSITIVE POWER

None (See Item 4)
  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

465,000 (See Item 4)
10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES*  ☐

Not Applicable
11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (9)

2.17%
12

TYPE OF REPORTING PERSON*

OO

* SEE INSTRUCTIONS BEFORE FILLING OUT.

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 13 of 30 – SEC Filing

CUSIP No. 867328700 Page
13
of 30 Pages
  1 

NAMES OF
REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Atlas Fundamental Trading Fund, Ltd.
  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP*

(a)  ☐        (b)  ☐
  3

SEC USE ONLY
  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

Cayman

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 5   

SOLE VOTING POWER

465,000
6

SHARED VOTING POWER

None (See Item 4)
7

SOLE DISPOSITIVE POWER

465,000
8

SHARED DISPOSITIVE POWER

None (See Item 4)
  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

465,000 (See Item 4)
10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES*  ☐

Not Applicable
11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (9)

2.17%
12

TYPE OF REPORTING PERSON*

CO

* SEE INSTRUCTIONS BEFORE FILLING OUT.

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 14 of 30 – SEC Filing

CUSIP No. 867328700 Page
14
of 30 Pages
  1 

NAMES OF
REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Balyasny Asset Management L.P.
  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP*

(a)  ☐        (b)  ☐
  3

SEC USE ONLY
  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 5   

SOLE VOTING POWER

2,000,000 (See Item 4)
6

SHARED VOTING POWER

None
7

SOLE DISPOSITIVE POWER

2,000,000 (See Item 4)
8

SHARED DISPOSITIVE POWER

None
  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,000,000 (See Item 4)
10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES*  ☐

Not Applicable
11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (9)

9.32%
12

TYPE OF REPORTING PERSON*

IA

* SEE INSTRUCTIONS BEFORE FILLING OUT.

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 15 of 30 – SEC Filing

CUSIP No. 867328700 Page
15
of 30 Pages
  1 

NAMES OF
REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Dmitry Balyasny
  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP*

(a)  ☐        (b)  ☐
  3

SEC USE ONLY
  4

CITIZENSHIP OR PLACE OF
ORGANIZATION

United States

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 5   

SOLE VOTING POWER

2,000,000 (See Item 4)
6

SHARED VOTING POWER

None
7

SOLE DISPOSITIVE POWER

2,000,000 (See Item 4)
8

SHARED DISPOSITIVE POWER

None
  9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,000,000 (See Item 4)
10

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (9) EXCLUDES CERTAIN SHARES*  ☐

Not Applicable
11

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (9)

9.32%
12

TYPE OF REPORTING PERSON*

IN

* SEE INSTRUCTIONS BEFORE FILLING OUT.

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 16 of 30 – SEC Filing

Item 1         (a) Name of Issuer:
Sunesis Pharmaceuticals, Inc. (the Company)
(b) Address of Issuers Principal Executive Offices:
395 Oyster Point Boulevard, Suite 400
South San Francisco, CA 94080
United States
Item 2 (a)  (c) This statement is filed on behalf of the following:

(1) Atlas Master Fund, Ltd. is a Cayman corporation (AMF), with its principal business
office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies.

(2) Atlas Global, LLC is a Delaware limited liability company (AG), with its principal
business office at 181 West Madison, Suite 3600, Chicago, IL 60602. AG owns 20.43% of the equity interests in AMF.

(3) Atlas Global Investments, Ltd. is a Cayman corporation (AGI), with its principal
business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies. AGI owns 34.78% of the equity interests in AMF.

(4) Atlas Institutional Fund, LLC is a Delaware limited liability company (AIF LLC), with its
principal business office at 181 West Madison, Suite 3600, Chicago, IL 60602. AIF LLC owns 8.55% of the equity interests in AMF.

(5) Atlas Institutional Fund, Ltd. is a Cayman corporation (AIF LTD), with its principal
business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies. AIF LTD owns 23.83% of the equity interests in AMF.

(6) Atlas Global Japan Unit Trust is a Cayman exempted unit trust (AGJ), with its principal
business office at c/o CIBC Bank and Trust Company (Cayman) Limited, CIBC Financial Centre, 11 Dr. Roys Drive-3rd Floor, P.O. Box 694, Grand Cayman, Cayman Islands, British West
Indies. AGJ owns 11.97% of the equity interests in AMF.

(7) Atlas Enhanced Master Fund, Ltd. is a Cayman corporation (AEMF), with its principal
business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies.

Page 16 of 30 Pages

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 17 of 30 – SEC Filing

(8) Atlas Enhanced Fund, L.P. is a Delaware limited partnership (AEF LP), with its principal
business office at 181 West Madison, Suite 3600, Chicago, IL 60602. AEF LP owns 30.90% of the equity interests in AEMF.

(9) Atlas Enhanced Fund, Ltd. is a Cayman corporation (AEF LTD), with its principal business
office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies. AEF LTD owns 69.09% of the equity interests in AEMF.

(10) Atlas Fundamental Trading Master Fund Ltd. is a Cayman corporation (AFT MASTER), with
its principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies.

(11) Atlas Fundamental Trading Fund, L.P., is a Delaware limited partnership (AFT LP), with
its principal business office at 181 West Madison, Suite 3600, Chicago, IL 60602. AFT LP owns 37.03% of the equity interests in AFT MASTER.

(12) Atlas Fundamental Trading Fund Ltd. is a Cayman corporation (AFT LTD), with its
principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies. AFT LTD owns 62.85% of the equity interests in AFT MASTER

(13) Balyasny Asset Management L.P. is a Delaware limited partnership (BAM), with its
principal business office at 181 West Madison, Suite 3600, and Chicago, IL 60602. BAM is the investment manager to each of AMF, AG, AGI, AIF LLC, AIF LTD, AGJ, AEMF, AEF LP, AEF LTD, AFT MASTER, AFT LP and AFT LTD.

(14)Dmitry Balyasny, a United States citizen whose business address is 181 West Madison, Suite 3600,
Chicago, IL 60602. Dmitry Balyasny is the sole managing member of the general partner of BAM.
(d) Title of Class of Securities:
Common Stock
(e) CUSIP Number: 867328700

Page 17 of 30 Pages

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 18 of 30 – SEC Filing

Item 3         If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
Not Applicable
Item 4         Ownership:
AMF
(a) Amount Beneficially Owned:
224,506
(b) Percent of Class:
1.05%
(c) Number of Shares as to which person has:
(i) Sole power to vote or to direct vote:
224,506
(ii) Shared power to vote or to direct vote:
None
(iii) Sole power to dispose or direct disposition of:
224,506
(iv) Shared power to dispose or to direct disposition of:
None
AG
(a) Amount Beneficially Owned:
By virtue of its ownership of 20.43% of the equity interest in AMF, AG may be deemed to beneficially own the 224,506 Shares of the Companys Common Stock beneficially owned by
AMF.

Page 18 of 30 Pages

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 19 of 30 – SEC Filing

(b) Percent of Class:
1.05%
(c) Number of Shares as to which person has:
(i) Sole power to vote or to direct vote:
224,506
(ii) Shared power to vote or to direct vote:
None
(iii) Sole power to dispose or direct disposition of:
224,506
(iv) Shared power to dispose or to direct disposition of:
None
AGI
(a) Amount Beneficially Owned:
By virtue of its ownership of 34.78% of the equity interest in AMF, AGI may be deemed to beneficially own the 224,506 Shares of the Companys Common Stock beneficially owned by AMF.
(b) Percent of Class:
1.05%
(c) Number of Shares as to which person has:
(i) Sole power to vote or to direct vote:
224,506
(ii) Shared power to vote or to direct vote:
None
(iii) Sole power to dispose or direct disposition of:
224,506

Page 19 of 30 Pages

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 20 of 30 – SEC Filing

(iv) Shared power to dispose or to direct disposition of:
None
AIF LLC
(a) Amount Beneficially Owned:
By virtue of its ownership of 8.55% of the equity interest in AMF, AIF LLC may be deemed to beneficially own the 224,506 Shares of the Companys Common Stock beneficially owned by AMF.
(b) Percent of Class:
1.05%
(c) Number of Shares as to which person has:
(i) Sole power to vote or to direct vote:
224,506
(ii) Shared power to vote or to direct vote:
None
(iii) Sole power to dispose or direct disposition of:
224,506
(iv) Shared power to dispose or to direct disposition of:
None

Page 20 of 30 Pages

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 21 of 30 – SEC Filing

AIF LTD
(a) Amount Beneficially Owned:
By virtue of its ownership of 23.83% of the equity interest in AMF, AIF LTD may be deemed to beneficially own the 224,506 Shares of the Companys Common Stock beneficially owned by AMF.
(b) Percent of Class:
1.05%
(c) Number of Shares as to which person has:
(i) Sole power to vote or to direct vote:
224,506
(ii) Shared power to vote or to direct vote:
None
(iii) Sole power to dispose or direct disposition of:
224,506
(iv) Shared power to dispose or to direct disposition of:
None
AGJ
(a) Amount Beneficially Owned:
By virtue of its ownership of 11.97% of the equity interest in AMF, AGJ may be deemed to beneficially own the 224,506 Shares of the Companys Common Stock beneficially owned by AMF.
(b) Percent of Class:
1.05%

Page 21 of 30 Pages

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 22 of 30 – SEC Filing

(c) Number of Shares as to which person has:
(i) Sole power to vote or to direct vote:
224,506
(ii) Shared power to vote or to direct vote:
None
(iii) Sole power to dispose or direct disposition of:
224,506
(iv) Shared power to dispose or to direct disposition of:
None
AEMF
(a) Amount Beneficially Owned:
1,310,494
(b) Percent of Class:
6.11%
(c) Number of Shares as to which person has:
(i) Sole power to vote or to direct vote:
1,310,494
(ii) Shared power to vote or to direct vote:
None
(iii) Sole power to dispose or direct disposition of:
1,310,494
(iv) Shared power to dispose or to direct disposition of:
None

Page 22 of 30 Pages

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 23 of 30 – SEC Filing

AEF LP
(a) Amount Beneficially Owned:
By virtue of its ownership of 30.90% of the equity interest in AEMF, AEF LP may be deemed to beneficially own the 1,310,494 Shares of the Companys Common Stock beneficially owned by AEMF.
(b) Percent of Class:
6.11%
(c) Number of Shares as to which person has:
(i) Sole power to vote or to direct vote:
1,310,494
(ii) Shared power to vote or to direct vote:
None
(iii) Sole power to dispose or direct disposition of:
1,310,494
(iv) Shared power to dispose or to direct disposition of:
None
AEF LTD
(a) Amount Beneficially Owned:
By virtue of its ownership of 69.09% of the equity interest in AEMF, AEF LTD may be deemed to beneficially own the 1,310,494 Shares of the Companys Common Stock beneficially owned by AEMF.
(b) Percent of Class:
6.11%

Page 23 of 30 Pages

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 24 of 30 – SEC Filing

(c) Number of Shares as to which person has:
(i) Sole power to vote or to direct vote:
1,310,494
(ii) Shared power to vote or to direct vote:
None
(iii) Sole power to dispose or direct disposition of:
1,310,494
(iv) Shared power to dispose or to direct disposition of:
None
AFT MASTER
(a) Amount Beneficially Owned:
465,000
(b) Percent of Class:
2.17%
(c) Number of Shares as to which person has:
(i) Sole power to vote or to direct vote:
465,000
(ii) Shared power to vote or to direct vote:
None
(iii) Sole power to dispose or direct disposition of:
465,000
(iv) Shared power to dispose or to direct disposition of:
None

Page 24 of 30 Pages

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 25 of 30 – SEC Filing

AFT LP
(a) Amount Beneficially Owned:
By virtue of its ownership of 37.03% of the equity interest in AFT MASTER, AFT LP may be deemed to beneficially own the 465,000 Shares of the Companys Common Stock beneficially owned by AFT MASTER.
(b) Percent of Class:
2.17%
(c) Number of Shares as to which person has:
(i) Sole power to vote or to direct vote:
465,000
(ii) Shared power to vote or to direct vote:
None
(iii) Sole power to dispose or direct disposition of:
465,000
(iv) Shared power to dispose or to direct disposition of:
None
AFT LTD
(a) Amount Beneficially Owned:
By virtue of its ownership of 62.85% of the equity interest in AFT MASTER, AFT LTD may be deemed to beneficially own the 465,000 Shares of the Companys Common Stock beneficially owned by AFT MASTER.
(b) Percent of Class:
2.17%

Page 25 of 30 Pages

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 26 of 30 – SEC Filing

(c) Number of Shares as to which person has:
(i) Sole power to vote or to direct vote:
465,000
(ii) Shared power to vote or to direct vote:
None
(iii) Sole power to dispose or direct disposition of:
465,000
(iv) Shared power to dispose or to direct disposition of:
None
BAM
(a) Amount Beneficially Owned:
By virtue of its position as investment manager to each of AMF, AG, AGI, AIF LLC, AIF LTD, AGJ, AEMF, AEF LP, AEF LTD, AFT MASTER, AFT LP and AFT LTD, BAM may be deemed to beneficially own the 2,000,000 Shares of the
Companys Common Stock beneficially owned by AMF, AG, AGI, AIF LLC, AIF LTD, AGJ, AEMF, AEF LP, AEF LTD, AFT MASTER, AFT LP and AFT LTD.
(b) Percent of Class:
9.32%
(c) Number of Shares as to which person has:
(i) Sole power to vote or to direct vote:
2,000,000
(ii) Shared power to vote or to direct vote:
None

Page 26 of 30 Pages

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 27 of 30 – SEC Filing

(iii) Sole power to dispose or direct disposition of:
2,000,000
(iv) Shared power to dispose or to direct disposition of:
None
Dmitry Balyasny
(a) Amount Beneficially Owned:
By virtue of his position as the sole managing member of the general partner of BAM, Mr. Balyasny may be deemed to beneficially own the 2,000,000 Shares of the Companys Common Stock beneficially owned by
BAM.
(b) Percent of Class:
9.32%
(c) Number of Shares as to which person has:
(i) Sole power to vote or to direct vote:
2,000,000
(ii) Shared power to vote or to direct vote:
None
(iii) Sole power to dispose or direct disposition of:
2,000,000
(iv) Shared power to dispose or to direct disposition of:
None
Item 5         Ownership of Five Percent or Less of a Class:
Applicable
Item 6 Ownership of More than Five Percent on Behalf of Another Person:
Not Applicable

Page 27 of 30 Pages

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 28 of 30 – SEC Filing

Item 7         Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
Not Applicable
Item 8 Identification and Classification of Members of the Group:
Not Applicable
Item 9 Notice of Dissolution of Group:
Not Applicable
Item 10 Certification:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control
of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 28 of 30 Pages

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 29 of 30 – SEC Filing

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: July 5, 2017

ATLAS MASTER FUND, LTD. ATLAS GLOBAL, LLC
By:

/s/ Scott Schroeder

 By:

/s/ Scott Schroeder
Scott Schroeder Scott Schroeder
Authorized Signatory Authorized Signatory
ATLAS GLOBAL INVESTMENTS, LTD. ATLAS INSTITUTIONAL FUND, LLC
By:

/s/ Scott Schroeder

 By:

/s/ Scott Schroeder
Scott Schroeder Scott Schroeder
Authorized Signatory Authorized Signatory
ATLAS INSTITUTIONAL FUND, LTD. ATLAS GLOBAL JAPAN UNIT TRUST
By:

/s/ Scott Schroeder

 By:

/s/ Scott Schroeder
Scott Schroeder Scott Schroeder
Authorized Signatory Authorized Representative
ATLAS ENHANCED MASTER FUND, LTD. ATLAS ENHANCED FUND, L.P.
By:

/s/ Scott Schroeder

 By:

/s/ Scott Schroeder
Scott Schroeder Scott Schroeder
Authorized Signatory Authorized Signatory
ATLAS ENHANCED FUND, LTD. ATLAS FUNDAMENTAL TRADING MASTER FUND LTD.
By:

/s/ Scott Schroeder

 By:

/s/ Scott Schroeder
Scott Schroeder Scott Schroeder
Authorized Signatory Authorized Signatory

Page 29 of 30 Pages

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 30 of 30 – SEC Filing

ATLAS FUNDAMENTAL TRADING FUND, L.P. ATLAS FUNDAMENTAL TRADING FUND, LTD.
By:

/s/ Scott Schroeder

 By:

/s/ Scott Schroeder
Scott Schroeder Scott Schroeder
Authorized Signatory Authorized Signatory
BALYASNY ASSET MANAGEMENT L.P. DMITRY BALYASNY
By:

/s/ Scott Schroeder

 By:

/s/ Scott Schroeder
Scott Schroeder Scott Schroeder
Authorized Signatory Authorized Representative

Page 30 of 30 Pages

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Related Insider Monkey Articles
13G Filing: SQN Investors and Apptio Inc (APTI)13G Filing: Tiger Management and Ooma Inc (OOMA)
13G Filing: Biotechnology Value Fund LP and CytomX Therapeutics Inc (CTMX)13G Filing: Rutabaga Capital Management and Rutabaga Capital Management LLC
13G Filing: G2 Investment Partners Management and Datawatch Corp (DWCH)13G Filing: EJF Capital and Bank Of Commerce Holdings (BOCH)